• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

End of the Bedaquiline patent - a crucial development for moving forward affordable drugs, diagnostics, and vaccines for infectious diseases in low- and middle-income countries.

作者信息

Petersen Eskild, Hui David S, Nachega Jean B, Ntoumi Francine, Goletti Delia, Aklillu Eleni, Sharma Avinash, Nyirenda Thomas, Yeboah-Manu Dorothy, Satta Giovanni, da Costa Christopher, Azhar Esam I, Bockarie Moses, Al-Abri Seif, McHugh Timothy D, Rodriguez-Morales Alfonso J, Varghese George M, Zumla Alimuddin

机构信息

Institute for Clinical Medicine, Faculty of Health Sciences, University of Aarhus, Denmark; European Society for Clinical Microbiology and Infectious Diseases Task Force for Emerging Infections, Basel, Switzerland; International Society for Infectious Diseases.

Department of Medicine & Therapeutics and Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.

出版信息

Int J Infect Dis. 2023 Jun;131:180-182. doi: 10.1016/j.ijid.2023.04.386. Epub 2023 Apr 6.

DOI:10.1016/j.ijid.2023.04.386
PMID:37030652
Abstract
摘要

相似文献

1
End of the Bedaquiline patent - a crucial development for moving forward affordable drugs, diagnostics, and vaccines for infectious diseases in low- and middle-income countries.贝达喹啉专利到期——这是推动为低收入和中等收入国家提供负担得起的传染病药物、诊断方法和疫苗向前发展的一项关键进展。
Int J Infect Dis. 2023 Jun;131:180-182. doi: 10.1016/j.ijid.2023.04.386. Epub 2023 Apr 6.
2
Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?是否存在将质量有保证且价格可承受的药品带给低收入和中等收入国家的政治意愿？
Glob Health Action. 2019;12(1):1586317. doi: 10.1080/16549716.2019.1586317.
3
Considerations for combination vaccine development and use in the developing world.发展中国家联合疫苗研发与使用的考量因素。
Clin Infect Dis. 2001 Dec 15;33 Suppl 4:S340-5. doi: 10.1086/322571.
4
Improving access to affordable vaccines for middle-income countries in the african region.改善非洲区域中等收入国家获得负担得起的疫苗的机会。
Vaccine. 2019 May 9;37(21):2838-2842. doi: 10.1016/j.vaccine.2019.03.077. Epub 2019 Apr 9.
5
India Declines Patent Extension Application of Bedaquiline: A Remarkable Step Towards Tuberculosis Elimination.印度拒绝贝达喹啉的专利延期申请：迈向消除结核病的重要一步。
Cureus. 2023 Nov 2;15(11):e48146. doi: 10.7759/cureus.48146. eCollection 2023 Nov.
6
Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries.投资于五个主要传染病的后期临床试验和候选产品的生产：对三个中等收入国家投资的效益和成本的建模研究。
Lancet Glob Health. 2022 Jul;10(7):e1045-e1052. doi: 10.1016/S2214-109X(22)00206-6.
7
Prioritizing vaccines for developing world diseases.优先考虑针对发展中世界疾病的疫苗。
Vaccine. 2017 Jan 20;35 Suppl 1:A16-A19. doi: 10.1016/j.vaccine.2016.10.087. Epub 2016 Dec 22.
8
Tuberculosis结核病
9
Highly affordable vaccines are critical for our continued efforts to reduce global childhood mortality.高性价比疫苗对于我们持续降低全球儿童死亡率的努力至关重要。
Hum Vaccin Immunother. 2019;15(11):2660-2665. doi: 10.1080/21645515.2019.1605817. Epub 2019 May 17.
10
Perspectives on the development and use of economic evidence for immunization decision-making in a developing country.发展中国家免疫接种决策中经济证据的开发与应用展望
Vaccine. 2015 May 7;33 Suppl 1:A6-7. doi: 10.1016/j.vaccine.2014.12.048.

引用本文的文献

1
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens.新型结核病治疗方案的TB-PRACTECAL临床试验成本分析
PLOS Glob Public Health. 2025 Apr 23;5(4):e0003759. doi: 10.1371/journal.pgph.0003759. eCollection 2025.
2
ApoE Mimetic Peptide COG1410 Kills via Directly Interfering ClpC's ATPase Activity.载脂蛋白E模拟肽COG1410通过直接干扰ClpC的ATP酶活性发挥杀伤作用。
Antibiotics (Basel). 2024 Mar 19;13(3):278. doi: 10.3390/antibiotics13030278.
3
India's Decision to Deny an Extension of Patent for Bedaquiline: A Public Health Imperative.
印度拒绝延长贝达喹啉专利期限的决定：一项公共卫生要务。
Cureus. 2023 Nov 28;15(11):e49542. doi: 10.7759/cureus.49542. eCollection 2023 Nov.
4
India Declines Patent Extension Application of Bedaquiline: A Remarkable Step Towards Tuberculosis Elimination.印度拒绝贝达喹啉的专利延期申请：迈向消除结核病的重要一步。
Cureus. 2023 Nov 2;15(11):e48146. doi: 10.7759/cureus.48146. eCollection 2023 Nov.